专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3600340A2 RANKING SYSTEM FOR IMMUNOGENIC CANCER-SPECIFIC EPITOPES 审中-实审转让
公开(公告)号：EP3600340A2
公开(公告)日：2020-02-05
申请号：EP18776882.5
申请日：2018-03-31
申请人： Pei-Jia, Yang , Cheng, Jen-hao , Chen, Ying-Ja , Chen, Shu-jen , Chen, Hua-chien
发明人： Pei-Jia, Yang , Cheng, Jen-hao , Chen, Ying-Ja , Chen, Shu-jen , Chen, Hua-chien
IPC分类号： A61K31/7052 , A61K31/7105 , A61K39/00 , A61K39/02 , A61K48/00 , C07H21/02

2. 发明专利

SG11201907738UA RANKING SYSTEM FOR IMMUNOGENIC CANCER-SPECIFIC EPITOPES 未知
公开(公告)号：SG11201907738UA
公开(公告)日：2019-09-27
申请号：SG11201907738U
申请日：2018-03-31
申请人： PEI JIA YANG , CHENG JEN HAO , CHEN YING JA , CHEN SHU JEN , CHEN HUA CHIEN
发明人： PEI-JIA YANG , CHENG JEN-HAO , CHEN YING-JA , CHEN SHU-JEN , CHEN HUA-CHIEN
IPC分类号： A61K31/7105 , A61K31/7052 , A61K39/00 , A61K39/02 , A61K48/00 , C07H21/02
摘要： Epitopeidentification Component computation 'Mathirieleething m odel Weight assignment Peptide-level score designation Sample-level score designation Immunogenicity score designation () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT ~~~~~~~~~~~~~ 011101010VIIIOH olo HE mil mo lio (10) International Publication Number WO 2018/183980 A3 (51) International Patent Classification: A61K 31/7052 (2006.01) A61K 39/02 (2006.01) A61K 31/7105 (2006.01) A61K 48/00 (2006.01) A61K 39/00 (2006.01) C07H 21/02 (2006.01) (21) International Application Number: PCT/US2018/025597 (22) International Filing Date: 31 March 2018 (31.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/479,320 31 March 2017 (31.03.2017) US (72) Inventors; and (71) Applicants: PEI-JIA, Yang; 4f, No.208, Xinhu 2nd Rd, Neihu Dist, Taipei City, 114 (TW). CHENG, Jen-Hao; 4f, No.208, Xinhu 2nd Rd, Neihu Dist, Taipei City, 114 (TW). CHEN, Ying-Ja [US/ ]; 4f, No.208, Xinhu 2nd Rd, Nei- hu Dist, Taipei City, 114 (TW). CHEN, Shu-Jen [US/ ]; 2f.-1, No.69-1, Hejiang St., Zhongshan Dist., Taipei City, 104 (TW). CHEN, Hua-Chien; 4f., No. 17, Ln. 63, Sec. 2, Dunhua S. Rd. Daan Dist., Taipei City, 106 (TW). (74) Agent: KAO, Laurence; OPES IP CONSULTING CO., LTD, 4f. No.203, Sec. 1, Fuxing S. Rd., Daan Dist., Taipei City, 10666 (TW). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (54) Title: RANKING SYSTEM FOR IMMUNOGENIC CANCER-SPECIFIC EPITOPES Tumor 8f normal tis LIES Whole exome sequencing Variant deterrnina on Ranking FIGURE 1 (57) : This disclosure relates to systems and methods that identify, predict, and rank immunogenic T-cell epitopes. In particular, this disclosure identifies epitopes that arose from disease-associated mutations, wherein the epitopes are predicted to elicit immune response from T cells. Specifically, this disclosure simultaneously considers peptide-level information, including MHC Class I and II presentation, helper and cytotoxic T cell response and sample-level information, including mutation clonality and MHC allele dosage. In some embodiment, the systems and methods are used for personalized treatment of cancers. [Continued on next page] WO 2018/183980 A3 MIDEDIMOMOIDEIREEMOMiliMOIHMOMMEfin GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(i)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 20 December 2018 (20.12.2018)

3. 发明申请

WO2010002415A1 TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIA INFECTION 审中-公开
标题翻译：抗菌细菌感染的治疗
公开(公告)号：WO2010002415A1
公开(公告)日：2010-01-07
申请号：PCT/US2008/075549
申请日：2008-09-08
申请人： TAIGEN BIOTECHNOLOGY CO., LTD. , HSU, Ming-chu , KING, Chi-Hsin Richard , CHEN, Shu-Jen , LIN, Luke
发明人： HSU, Ming-chu , KING, Chi-Hsin Richard , CHEN, Shu-Jen , LIN, Luke
IPC分类号： A61K31/4409 , A61K31/4709 , A61P31/04
CPC分类号： A61K31/4709
摘要： This invention relates to a method of treating infection by methicillin-nonsusceptibale bacteria, vancomycin-nonsusceptibale bacteria, penicillin-nonsusceptibale bacteria, clarithromycin-nonsusceptibale bacteria, or metronidazole-nonsusceptibale bacteria by administering to a subject in need thereof an effective amount of a quinolone compound of the formula shown in the specification.
摘要翻译：本发明涉及一种通过向有需要的受试者施用有效量的喹诺酮化合物来治疗甲氧西林 - 非感染性细菌，万古霉素 - 非吸收性细菌，青霉素 - 非吸收性细菌，克拉霉素 - 非吸收性细菌或甲硝唑 - 非受体细菌感染的方法的说明书中所示的公式。

4. 发明申请

WO2008021788A3 POLYAMINE COMPOUNDS 审中-公开
公开(公告)号：WO2008021788A3
公开(公告)日：2008-02-21
申请号：PCT/US2007/075265
申请日：2007-08-06
申请人： TAIGEN BIOTECHNOLOGY CO., LTD. , YEN, Chi-Feng , WU, Chien-Huang , HUANG, Ying-Huey , KING, Chi-Hsin, Richard , CHEN, Shu-Jen , CHEN, Hua-chien , HAKIMELAHI, Gholam, Hossein
发明人： YEN, Chi-Feng , WU, Chien-Huang , HUANG, Ying-Huey , KING, Chi-Hsin, Richard , CHEN, Shu-Jen , CHEN, Hua-chien , HAKIMELAHI, Gholam, Hossein
IPC分类号： A61K31/40 , A61K31/165 , A61K31/18
摘要： This invention relates to methods for treating retinopathy and repairing tissue damage. The methods include administering to a subject in need thereof an effective amount of one or more compounds of the following formula (I): Each variable in this formula is defined in the specification.

5. 发明申请

WO2008021788A2 POLYAMINE COMPOUNDS 审中-公开
标题翻译：多胺化合物
公开(公告)号：WO2008021788A2
公开(公告)日：2008-02-21
申请号：PCT/US2007075265
申请日：2007-08-06
申请人： TAIGEN BIOTECHNOLOGY CO LTD , YEN CHI-FENG , WU CHIEN-HUANG , HUANG YING-HUEY , KING CHI-HSIN RICHARD , CHEN SHU-JEN , CHEN HUA-CHIEN , HAKIMELAHI GHOLAM HOSSEIN
发明人： YEN CHI-FENG , WU CHIEN-HUANG , HUANG YING-HUEY , KING CHI-HSIN RICHARD , CHEN SHU-JEN , CHEN HUA-CHIEN , HAKIMELAHI GHOLAM HOSSEIN
IPC分类号： A61K31/65
CPC分类号： A61K31/65
摘要： This invention relates to methods for treating retinopathy and repairing tissue damage. The methods include administering to a subject in need thereof an effective amount of one or more compounds of the following formula (I): Each variable in this formula is defined in the specification.
摘要翻译：本发明涉及治疗视网膜病和修复组织损伤的方法。该方法包括向有需要的受试者施用有效量的一种或多种下式（I）的化合物：该式中的每个变量在说明书中定义。

6. 发明申请

WO2006138304A3 PYRIMIDINE COMPOUNDS 审中-公开
标题翻译：吡嗪化合物
公开(公告)号：WO2006138304A3
公开(公告)日：2007-05-24
申请号：PCT/US2006022975
申请日：2006-06-13
申请人： TAIGEN BIOTECHNOLOGY CO LTD , YEN CHI-FENG , HU CHENG-KUNG , CHOU MING-CHEN , TSENG CHEN-TSO , WU CHIEN-HUANG , HUANG YING-HUEY , CHEN SHU-JEN , KING CHI-HSIN RICHARD
发明人： YEN CHI-FENG , HU CHENG-KUNG , CHOU MING-CHEN , TSENG CHEN-TSO , WU CHIEN-HUANG , HUANG YING-HUEY , CHEN SHU-JEN , KING CHI-HSIN RICHARD
IPC分类号： A61K31/5377 , A61K31/496 , A61K31/505 , C07D239/42 , C07D403/04 , C07D413/06
CPC分类号： C07D239/48 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K38/193 , C07D239/42 , C07D239/50 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , A61K2300/00
摘要： This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the specification.
摘要翻译：本发明涉及一种治疗炎性疾病或免疫疾病，发育性或退行性疾病或组织损伤的方法。该方法包括向有需要的受试者施用有效量的一种或多种式（I）化合物。该公式中的每个变量在规范中定义。

7. 发明申请

WO2021041765A2 KIT AND METHODS TO DETECT NTRK GENE FUSION 审中-公开
公开(公告)号：WO2021041765A2
公开(公告)日：2021-03-04
申请号：PCT/US2020/048333
申请日：2020-08-28
申请人： HSU, An , LIN, Pei-Yi , WEI, Datsen George , CHEN, Shu-Jen , CHEN, Hua-Chien
发明人： HSU, An , LIN, Pei-Yi , WEI, Datsen George , CHEN, Shu-Jen , CHEN, Hua-Chien
IPC分类号： C12Q1/6876 , C12Q1/6844 , C12Q1/6813 , C07K14/705 , C12Q1/6816 , C12Q1/6886
摘要： Provided is a kit for detecting neurotrophin receptor tyrosine kinase (NTRK) gene fusion. The kit includes a set of NTRK fusion-specific primer pairs and a set of NTRK fusion-specific probes. Also provided is a method for detecting NTRK gene fusion, including generating an amplified target cDNA to hybridize with the set of NTRK fusion-specific probes in a single reaction, and detecting the probe-bound product to identify all possible NTRK gene fusions in a biological sample.

8. 发明申请

WO2018183980A3 RANKING SYSTEM FOR IMMUNOGENIC CANCER-SPECIFIC EPITOPES 审中-公开
公开(公告)号：WO2018183980A3
公开(公告)日：2018-10-04
申请号：PCT/US2018/025597
申请日：2018-03-31
申请人： PEI-JIA, Yang , CHENG, Jen-Hao , CHEN, Ying-Ja , CHEN, Shu-Jen , CHEN, Hua-Chien
发明人： PEI-JIA, Yang , CHENG, Jen-Hao , CHEN, Ying-Ja , CHEN, Shu-Jen , CHEN, Hua-Chien
IPC分类号： A61K31/7052 , A61K31/7105 , A61K39/00 , A61K39/02 , A61K48/00 , C07H21/02
摘要： This disclosure relates to systems and methods that identify, predict, and rank immunogenic T-cell epitopes. In particular, this disclosure identifies epitopes that arose from disease-associated mutations, wherein the epitopes are predicted to elicit immune response from T cells. Specifically, this disclosure simultaneously considers peptide-level information, including MHC Class I and II presentation, helper and cytotoxic T cell response and sample-level information, including mutation clonality and MHC allele dosage. In some embodiment, the systems and methods are used for personalized treatment of cancers.

9. 发明申请

WO2011126808A9 PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM 审中-公开
公开(公告)号：WO2011126808A9
公开(公告)日：2011-10-13
申请号：PCT/US2011/030213
申请日：2011-03-28
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , WILSON, James, M. , CHEN, Shu-Jen , TRETIAKOVA, Anna, P.
发明人： WILSON, James, M. , CHEN, Shu-Jen , TRETIAKOVA, Anna, P.
IPC分类号： C12N15/86 , C12N15/864 , A61K48/00
摘要： The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent - preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as "PITA" (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript.

10. 发明申请

WO2004091485A3 AMINOQUINOLINE COMPOUNDS 审中-公开
公开(公告)号：WO2004091485A3
公开(公告)日：2004-10-28
申请号：PCT/US2004/010695
申请日：2004-04-06
申请人： TAIGEN BIOTECHNOLOGY , LIN, Chu-Chung , LIU, Jen-Fuh , CHANG, Chih-Wei , CHEN, Shu-Jen , XIANG, Yibin , CHENG, Pei-Chin , JAN, Jiing-Jyh
发明人： LIN, Chu-Chung , LIU, Jen-Fuh , CHANG, Chih-Wei , CHEN, Shu-Jen , XIANG, Yibin , CHENG, Pei-Chin , JAN, Jiing-Jyh
IPC分类号： A61K31/4709
摘要： This invention relates to treating inflammatory and immune diseases with certain aminoquinoline compounds that bind to CXCR3 receptors. The aminoquinoline compounds are covered by the formula (I) shown below. Each variable is defined in the specification.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式